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Abstract
Background: Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare, X-linked disorder caused by
deficient activity of the enzyme iduronate-2-sulfatase (I2S). Treatment is available in the form of enzyme
replacement therapy (ERT) with recombinant I2S. Clinical outcomes following ≥3 years of ERT with idursulfase were
investigated in a broad population of patients with MPS II enrolled in the Hunter Outcome Survey (HOS).
Methods: As of January 2016, 639 patients (excluding female patients, individuals who had received a bone marrow
transplant and those enrolled in the phase 1/2 [TKT018] or phase 2/3 [TKT024] clinical trial) followed prospectively in
the registry had received idursulfase for ≥6 months. These individuals all had data available for ≥1 clinical parameter at
baseline and ≥1 additional time point following treatment initiation. Changes in clinical parameters were assessed in
the subcohorts of patients with a measurement at baseline and at year 1, 2 or 3 of treatment. Safety data from patients
who started treatment at or after enrollment in HOS (n = 233) were also assessed.
Results: Median (10th, 90th percentiles) age at first treatment was 6.2 (2.1, 18.2) years and median treatment duration
was 56.3 (18.2, 97.6) months. Urinary glycosaminoglycan (uGAG) levels decreased from baseline to year 3 in patients
with data available at this time point (median change from baseline: −201.0 [−591.4, −21.9] μg/mg creatinine
[n = 121]). Improvements in the following parameters were observed at year 3 in the subcohorts: 6-min walking test
(6MWT) distance, 10.6 (−33.6, 50.8)% (n = 26); left ventricular mass index (LVMI), −9.3 (−31.5, 19.7)% (n = 52); absolute
forced vital capacity (FVC), 29.7 (−13.4, 66.7)% (n = 23); absolute forced expiratory volume in 1 s (FEV1), 22.8 (−15.2, 62.1)
% (n = 22); palpable liver size, −54.5 (−85.7, 50.0)% (n = 53); palpable spleen size, −33.3 (−80.0, 33.3)% (n = 17). No new
or unexpected safety concerns were identified in this analysis.
Conclusions: These findings suggest that idursulfase has a positive effect on uGAG levels, 6MWT results, LVMI, FVC,
FEV1 and hepatosplenomegaly after 1, 2 and 3 years treatment.
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Background
Mucopolysaccharidosis type II (MPS II; Hunter syndrome;
OMIM 309900) is a rare, X-linked recessive, life-limiting
metabolic disease [1], with an estimated incidence of 0.6–
1.3 in 100,000 live male births [2, 3]. It is caused by defi-
cient activity of iduronate-2-sulfatase (I2S), a lysosomal
enzyme that catalyses a step in the catabolism of glycos-
aminoglycan (GAG). Accumulation of GAG in nearly all
tissues and organs contributes to the chronic, progressive,
multisystemic clinical signs and symptoms of MPS II [1].
Although somatic signs and symptoms are present in
all patients, the severity of MPS II spans a broad range
[1]. Around two-thirds of patients will develop central
nervous system (CNS) involvement with progressive
profound cognitive impairment [4]. Death occurs in the
first or second decade of life in patients with cognitive
impairment who are untreated, most commonly as a re-
sult of complications associated with obstructive airway
disease or cardiac failure [1, 5]. Disease progression is
often slower in individuals without cognitive impair-
ment, with patients with normal cognitive function typ-
ically surviving into adulthood [1, 5].
Significant improvements have been made in the man-
agement of MPS II over the last 2 decades, including ad-
vances in symptomatic care and the availability of disease-
specific treatments such as enzyme replacement therapy
(ERT) with recombinant I2S [4, 6]. Most clinical experi-
ence has been gathered with intravenously administered
idursulfase (Elaprase®, Shire, Lexington, MA, USA), al-
though other therapies for the treatment of MPS II are
currently in development. Improvements in clinical pa-
rameters such as forced vital capacity (FVC) and distance
walked in the 6-min walk test (6MWT), as well as de-
creases in liver and spleen size (as measured by magnetic
resonance imaging) and urinary GAG (uGAG) levels have
been demonstrated in clinical trials of intravenous idursul-
fase in patients with MPS II [7–9]. A recent analysis of
data from the Hunter Outcome Survey (HOS) also dem-
onstrated improved survival in patients who received idur-
sulfase compared with those who were untreated [10]. In
addition, idursulfase has been shown to be generally well
tolerated, with a safety profile similar to that reported for
ERT in patients with other mucopolysaccharidoses [7–9,
11–14]. However, long-term follow-up is particularly
important for gaining a better understanding of disease
progression and for evaluating the efficacy of ERT, par-
ticularly in routine clinical practice.
The Hunter Outcome Survey (HOS) is a large, multicen-
tre, observational registry established in 2005 and collects
long-term data on the natural history of MPS II and the ef-
ficacy and safety of ERT with idursulfase [4, 5, 15–23]. Data
were analysed to investigate clinical outcomes following up
to 3 years of idursulfase treatment in a broad population of
patients with MPS II.
Methods
Registry design and data collection
HOS is designed to collect data on patients with MPS II
based on information obtained during routine patient
visits and assessments [4]. The registry is open to all pa-
tients with MPS II who are untreated or who are receiv-
ing treatment with idursulfase; patients receiving any
other form of ERT are excluded. A wide range of infor-
mation, including demographic and clinical data, is cap-
tured; however, there are no predetermined assessments
in the registry. As such, patient visits and assessments
occur as deemed appropriate by the treating physician
and all investigations are performed using the methods
and techniques commonly employed at each clinic. Data
can be entered from patients who are alive at study en-
rollment (prospective patients), and also from individ-
uals who are deceased at enrollment (historical patients)
if local regulations permit. Before enrollment, Independ-
ent Review Board/Ethics Committee approval was ob-
tained for all participating centres. Written informed
consent was obtained from each patient, their parents or
legal representative. All patient information is managed
in accordance with national data protection standards.
The presence of cognitive involvement was determined
based on the answer to the following question: ‘Cogni-
tive impairment? Yes/No′ for the period from birth to
HOS entry and at subsequent visits (i.e. at any time).
The answer to this question is based on either the re-
sults of standardized cognitive tests, or on the clinical
impression of the treating physician.
Functional classification was collected in the database
based on the clinical impression of the attending phys-
ician and classed as ‘normal’ (approximate intelligence
quotient [IQ] >80), ‘borderline’ (IQ 70–80), ‘educable’
(IQ 50–70), ‘trainable’ (IQ 30–50) or ‘profoundly im-
paired’ (IQ <30). These categories correspond to, but are
not identical to, the severity levels for intellectual dis-
ability described in the Diagnostic and Statistical Manual
of Mental Disorders, fourth edition (DSM-IV) (Ameri-
can Psychiatric Association, 2000) [24]. A functional
classification of ‘educable’ in the registry corresponds to
‘mild’ in the DSM-IV (IQ 50/55–70), ‘trainable’ to ‘mod-
erate’ (IQ 35/50–50/55), and ‘profoundly impaired’ to
‘severe’ and ‘profound’ severity (IQ <35/40).
Adverse events (AEs) are recorded in the HOS data-
base. The seriousness of an AE (serious or non-serious),
its relationship to treatment with idursulfase (not re-
lated, possibly related or probably related to treatment),
as well as severity of the AE (mild, moderate or severe)
can be entered in the database. An infusion-related reac-
tion is defined in the HOS protocol as an AE that occurs
during an infusion or up to 24 h post-infusion and for
which there is evidence of a causal relationship with
idursulfase. AEs entered in HOS are coded using the
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Medical Dictionary for Regulatory Activities (MedDRA;
version 16.0). Events that were not MedDRA coded
owing to lack of information are listed as ‘Not coded’.
Coded AEs were grouped by system organ class and pre-
ferred term; patients were counted only once within
each system organ class and preferred term.
Patient population
As of January 2016, 1096 individuals (prospective and
historical patients) were enrolled from 124 centres in 29
countries. Of these patients, 947 were alive at HOS entry
and were followed prospectively in the registry; the
remaining 149 were deceased at enrollment and had
data entered retrospectively.
Male patients who had received idursulfase for at least
6 months and who were followed prospectively were
included in this analysis. These individuals all had data
available for at least one clinical parameter at baseline and
at least one additional time point following treatment initi-
ation. Female patients, individuals who were enrolled in the
phase 1/2 (TKT018) or phase 2/3 (TKT024) trial, and those
who had received a bone marrow transplant were excluded.
Two individuals received treatment with intrathecally
delivered idursulfase via participation in a clinical trial
(SHP609-302, ClinicalTrials.gov identifier: NCT02412787)
and so were no longer eligible to participate in HOS; for
these patients, data after the date of surgical implantation
of the intrathecal drug delivery device were not included in
this analysis.
Data analysis
Improvements in clinical parameters following ERT with
idursulfase have been found to be particularly pronounced
within the first year of treatment [25, 26]. Therefore, clin-
ical and biochemical measures recorded at annual time
points over 3 years (data collected at any point between
study start [2005] and January 2016) were compared with
baseline values. The baseline measurement was defined as
the last recorded measurement in the 12 months preced-
ing the start of idursulfase treatment.
A post-baseline measurement was defined as the value
recorded closest to the 1st, 2nd or 3rd-year anniversary of
the baseline measurement, within 6 months either side of
the anniversary date. If there were two values within equal
times of the evaluation visit, the first value was used. Se-
lected parameters were assessed in the subcohort of pa-
tients with a measurement at baseline and at year 1, 2 or 3
of treatment. For each clinical parameter, the subcohort at
year 1 comprised patients with data available on that par-
ameter at both baseline and year 1; the subcohort at year
2 comprised patients with data available at both baseline
and year 2; the subcohort at year 3 comprised patients
with data available at both baseline and year 3. An
additional analysis of uGAG values was performed using
data only from patients who had a measurement at all
time points (baseline, year 1, year 2 and year 3). uGAG
values recorded in the database were obtained either from
a local laboratory or from a central laboratory (analyses of
uGAG levels were conducted by the Shire central labora-
tory between 3 October 2005 and 28 February 2014; ana-
lyses conducted after 1 March 2014 were performed by
LabCorp). uGAG levels were determined by methods used
in the local or central laboratories. uGAG values included
in this analysis may have been determined by different
methods and therefore as well as absolute changes, per-
centage changes from baseline are presented to give an in-
dication of general trends. Left ventricular mass index
(LVMI) was calculated from an echocardiogram using the
Devereux formula [27] and adjusted for body surface area
using the closest height or weight measurement taken
within 91.5 days either side of the investigation date. Left
ventricular hypertrophy (LVH) was defined as an LVMI
greater than 102 g/m2. For analysis of pulmonary mea-
sures and 6MWT distance, only data from patients aged
at least 5 years at the date of assessment were included. In
addition, data from those patients who required assistance
to complete the 6MWT were excluded. Liver and spleen
sizes were obtained using palpation according to standard
clinical practice at each centre [18, 28].
To investigate the incidence of serious AEs (SAEs) occur-
ring during idursulfase treatment, data on SAEs were
analysed in those patients who started ERT with idursulfase
at or after enrollment in HOS (n = 233). AEs occurring
during the period of enrollment, including a description of
the event, its timing, severity and any possible or probable
relationship with idursulfase (judged by the attending
physician), were recorded in the registry by the clinic.
Events were coded as either infusion-related or not
infusion-related; the former was defined as events occurring
during or within 24 h of an infusion and with evidence of a
causal relationship with idursulfase.
Statistical methods
Summary tabulations of the number and percentage of
subjects within each category are presented for categorical
variables. For continuous variables, the number of individ-
uals and median values (10th and 90th percentiles) are
presented. A t-test was used to test for the significance in
change from baseline to year 3 between positive and
negative groups in the antibody status and neutralizing
antibody status groups.
Results
Patient population
In total, 639 male patients in HOS had received idursulfase
for at least 6 months, were alive at HOS entry, had not
received a bone marrow transplant and had not participated
in the TKT018 or TKT024 trial. The median (10th, 90th
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percentiles) age at treatment start in these patients was 6.2
(2.1, 18.2) years and the median duration of treatment was
56.3 (18.2, 97.6) months. The demographic and baseline
characteristics for these patients are shown in Table 1.
Cognitive impairment at any time was recorded for
61.5% (385/626) of the patients with available information.
Last-reported functional classification was available for
73.1% (467/639) of patients. Of these 467 patients, 38.3%
were considered ‘normal’, 10.9% ‘borderline’, 8.6% ‘educ-
able’, 15.2% ‘trainable’ and 27.0% ‘profoundly impaired’.
A total of 97 patients died after enrollment (median
[10th, 90th percentiles] age at death, 15.9 [10.6, 28.0]
years). Of these individuals, 94 had information on cog-
nitive impairment available; 75 were reported to have
cognitive involvement. The most commonly reported
causes of death were respiratory failure (39%; n = 38),
causes classified as ‘other’ (35%; n = 34) and cardiac ar-
rest (12%; n = 12). The median age at treatment start in
these patients was 10.7 (6.0, 25.2) years and the median
duration of treatment was 27.4 (7.5, 86.5) months.
Clinical outcomes
Changes in clinical parameters were assessed in the sub-
cohort of patients for whom measurements at baseline
and at year 1 or 2 or 3 of treatment were available. It is
important to note that the sample sizes at each time point
differed and the number of patients with baseline and
post-baseline data available was low for some parameters.
The number of patients with data available at the three
time points for the various parameters assessed ranged
from 17 to 177 (as specified in Figs. 1, 2, 3, 4, 5 and 6 and
Additional file 1: Table S1).
Change in uGAG levels
uGAG values were determined by either a local laboratory
or a central laboratory using the standard method used at
that laboratory. Median uGAG levels were consistently de-
creased from baseline at all three time points following
treatment with idursulfase (Fig. 1a, Additional file 1: Table
S1A). The median (10th, 90th percentiles) change in uGAG
levels at year 1, year 2 and year 3 was −160.6 (−550.0, 4.2),
−166.3 (−555.3, 18.5) and −201.0 (−591.4, −21.9) μg/mg
creatinine, respectively. Of the individuals included in this
analysis, 83 had data on uGAG levels available at all time
points (years 1, 2 and 3); a similar trend in change from
baseline in uGAG levels was observed in this subgroup of
patients (Fig. 1c, Additional file 2: Table S2).
6MWT
Baseline 6MWT distance was typically less than that of an
age-matched reference population (Fig. 2a) [29]. Median
distance walked was increased compared with baseline for
each subcohort (i.e. year 1, year 2 and year 3) (Fig. 2b & c,
Additional file 1: Table S1B). In those patients with data
available at year 3 (n = 26), the median change from base-
line was 41.0 (−138.0, 158.0) m, corresponding to a median
percentage change from baseline of 10.6 (−33.6, 50.8)%.
LVMI
There was a reduction from baseline in LVMI at each year
of treatment (Fig. 3, Additional file 1: Table S1C). In those
patients with year 3 data (n = 52), the median (10th, 90th
percentiles) change from baseline was −8.5 (−30.5, 19.3)
g/m2, corresponding to a median percentage change from
baseline of −9.3 (−31.5, 19.7)%. In patients without LVH at
baseline, LVMI did not increase compared with baseline
over the 3 years of treatment (year 3, −2.8 [−25.3, 58.7] g/
m2; n = 40; median age, 8.4 [5.2, 17.3] years). Of the 40 pa-
tients without LVH at baseline and for whom data follow-
ing 3 years of treatment were available, six were reported
to have LVH at year 3. For patients with LVH at baseline,
there was a general trend towards decreased LVMI with
treatment, although patient numbers were limited (year 3:
−23.5 [−67.7, −9.9] g/m2, n = 12; median age, 13.4 [9.0,
24.2] years).
Table 1 Demographics and baseline characteristics of patients
included in the analysis
Patients, N = 639
Age at onset of symptoms, years (n = 517) 1.5 (0.3, 4.0)
Age at diagnosis, years (n = 582) 3.1 (1.0, 6.7)
Age at first treatment, years 6.2 (2.1, 18.2)
Age at first treatment, n (%)
0–5 years 310 (48.5)
6–11 years 189 (29.6)
12–17 years 75 (11.7)
18–29 years 45 (7.0)
> 29 years 20 (3.1)
Time on treatment, months 56.3 (18.2, 97.6)
Time in HOS, months 46.8 (9.6, 93.0)
Treatment started at or after HOS entry, n (%) 233 (36.5)
Deceased, n (%) 97 (15.2)
Age at death, years (n = 97) 15.9 (10.6, 28.0)
Cognitive impairment (at any time), n (%) (n = 626)
Yes 385 (61.5)
No 241 (38.5)
Last-reported functional classification, n (%) (n = 467)
Normal 179 (38.3)
Borderline 51 (10.9)
Educable 40 (8.6)
Trainable 71 (15.2)
Profoundly impaired 126 (27.0)
Data are presented as median (10th, 90th percentiles) unless stated otherwise.
Data were available for all patients included in the analysis (N = 639) unless
stated otherwise. HOS, Hunter Outcome Survey
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Absolute FVC and FEV1
There was an increase from baseline in absolute FVC at
each year of treatment (Fig. 4, Additional file 1: Table S1D).
The median (10th, 90th percentiles) change from baseline
in the year 3 subcohort was 0.3 (−0.2, 1.1) L (n = 23), corre-
sponding to a median change from baseline of 29.7 (−13.4,
66.7)%. Absolute FEV1 was also increased at years 1 and 3,
compared with baseline (Fig. 5, Additional file 1: Table
S1E). In the patients with year 3 data, the median increase
was 0.2 (−0.3, 0.9) L (n = 22), corresponding to a median
change from baseline of 22.8 (−15.2, 62.1)%.
Palpable liver and spleen sizes
Liver and spleen sizes were measured by palpation accord-
ing to standard clinical practice at each centre. Of the 165
patients for whom data on palpable liver size was available
at baseline and year 3, and whose liver was palpable at
baseline, 103 (62.4%) no longer had a palpable liver after
treatment at year 3. Reductions in liver size compared
with baseline were observed at each time point for those
patients whose liver was palpable (Fig. 6a, Additional file
1: Table S1F). In those with data at year 3 (n = 53), the
median (10th, 90th percentiles) palpable liver size at base-
line was 6.0 (3.0, 11.0) cm and the median change from
baseline was −3.5 (−8.0, 1.0) cm. Of the 108 patients for
whom data on palpable spleen size was available at base-
line and year 3, and whose spleen was palpable at baseline,
85 (78.7%) no longer had a palpable spleen after treatment
at year 3. Spleen size was found to have decreased com-
pared with baseline at each time point in those patients
whose spleen was palpable (Fig. 6b, Additional file 1: Table
S1G). In those with data available after 3 years of treat-
ment (n = 17), the median palpable spleen size at baseline
was 5.0 (1.5, 9.0) cm and the median change from baseline
was −2.0 (−5.0, 0.5) cm.
Safety analyses
Of the patients included in this analysis, 233 started treat-
ment at or after HOS entry. A total of 1910 AEs were re-
ported in 174 (74.7%)) of these patients between treatment
start and the period of follow-up recorded in the registry. A
total of 80 patients (34.3%) experienced at least one drug-
related AE, 81 (34.8%) experienced at least one infusion-
related AE and 34 (14.6%) experienced at least one severe
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Fig. 1 Change in urinary glycosaminoglycan (uGAG) levels. a Absolute change and (b) percentage change from baselinea in uGAG levels in patients
with data available after 1, 2 or 3 years of treatment with idursulfase. c Absolute change and (d) percentage change from baseline in uGAG levels in
patients with data available at consecutive time points (year 1, year 2 and year 3 of treatment with idursulfase). Box plots illustrate the 25th, 50th
(median) and 75th percentiles (boxes) and the 10th and 90th percentiles (whiskers). aThe baseline measurement was defined as the last recorded
measurement in the 12 months preceding the start of idursulfase treatment. A post-baseline measurement was defined as the value recorded closest
to the 1st, 2nd or 3rd-year anniversary of the baseline measurement, within 6 months either side of the anniversary date. If there were two values
within equal times of the evaluation visit, the first value was used. uGAG values for each patient may have been determined by different methods;
therefore, absolute changes and percentage changes from baseline in uGAG levels are presented to give an indication of general trends
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AE. The most commonly reported AEs were those classi-
fied as infections and infestations, followed by respiratory,
thoracic and mediastinal disorders. Of the AEs, 67.6%
(1291/1910) were considered not related to treatment,
14.3% (273/1910) were considered probably related to treat-
ment and 11.9% (227/1910) possibly related to treatment.
Information on relationship to treatment was missing for
6.2% (119/1910) AEs. Of the 273 events considered prob-
ably related to treatment, 139 were mild in severity, 88 were
moderate, 21 were severe and 8 were life-threatening. Of
the 227 events classed as possibly related to treatment, 127
were considered mild in severity, 77 were moderate, 6 were
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recorded closest to the 1st, 2nd or 3rd-year anniversary of the baseline measurement, within 6 months either side of the anniversary date. If there
were two values within equal times of the evaluation visit, the first value was used
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severe and 7 were considered life-threatening. Of the 1910
AEs reported, 513 (26.9%) were recorded as infusion-
related reactions; system organ class and preferred term for
these are shown in Additional file 3: Table S3.
Discussion
This study is the first analysis of real-world data from a
large, broad population of patients on clinical outcomes
following up to 3 years of treatment with idursulfase.
Our results show improvements in uGAG levels, 6MWT
distance, LVMI, absolute FVC, absolute FEV1 and palp-
able liver and spleen size compared with baseline after 1,
2 and 3 years of treatment. In addition, the results of an
analysis of AEs in patients who started treatment at or
after enrolment in the registry were consistent with the
known safety profile of idursulfase, and two-thirds of the
AEs reported were not considered related to treatment.
Overall, this study suggests that idursulfase treatment
has a positive effect on somatic disease symptoms in pa-
tients with MPS II in routine clinical practice.
The clinical parameters analysed were selected to
match the endpoints studied in the phase 2/3 clinical
trial of intravenous idursulfase in patients with MPS II,
the 2-year open-label extension period, as well as a
phase 4 open-label single-arm study of idursulfase treat-
ment in boys with MPS II who were less than 5 years of
age [7–9]. Our findings are broadly in line with the re-
sults from these trials and other smaller studies [25, 26,
30–34]. In particular, we found that distance walked in
the 6MWT was increased compared with baseline at
each time point in the analysis populations and there
was also an increase from baseline in absolute FVC and
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FEV1. Although the numbers of patients with data avail-
able at year 3 for these parameters (6MWT, n = 26;
FVC, n = 23; FEV1, n = 22) are lower than the number
of patients included in the open-label extension period
of the phase 2/3 trial (n = 94), our results show that
idursulfase has positive effects when administered in a
routine clinical setting. It is important to note that FVC
and FEV1 are known to increase with height and age
[35]. Several studies have demonstrated that ERT has a
positive influence on height [8, 22] and so the improve-
ments observed in our analysis may be due to the
growth of the patients and the effect of ERT.
We observed decreases in uGAG levels compared with
baseline at all time points studied, and a similar result was
also seen in a subgroup of patients who had data available
at consecutive time points (years 1, 2 and 3 of treatment). It
should be noted that there are several limitations associated
with the uGAG data presented in our analysis. First, uGAG
values recorded in HOS are not all determined by the same
laboratory and as such, the values reported for each patient
may have been determined by different methods. In
addition, uGAG levels are known to vary with age [36], and
the ages of the patients included in this analysis with avail-
able data on uGAGs ranged from 0.0 to 48.0 years at base-
line (n = 242). As a result it was not possible to analyse the
changes in uGAG levels in relation to established reference
ranges. Finally, it is possible that the analysis of uGAG
levels may have been biased towards those patients with
less severe disease, as the collection of urine (and its subse-
quent analysis) may be more difficult in patients with severe
cognitive impairment. Nonetheless our findings do show a
general trend towards decreased uGAG levels in response
to treatment, which is consistent with another study of 27
paediatric patients treated with idursulfase for 3.5 years out-
side of a clinical trial setting [25].
Consistent with findings from the phase 1/2 study and
other small-scale studies on the effectiveness of idursulfase
[26, 30, 32, 34], we observed improvements in LVMI com-
pared with baseline with each year of treatment in our ana-
lysis. Although the patient numbers in our analysis were
too small to mathematically evaluate any formal relation-
ship between the development of hypertrophic cardiomy-
opathy and treatment with idursulfase, it is recognized that
this condition is frequently reported in untreated patients
with mucopolysaccharidoses, and in MPS II in particular
[37]. The literature demonstrates that cardiomyopathy is
part of the underlying manifestation of MPS II and not a
likely complication of ERT with idursulfase [37].
Palpable liver and spleen sizes were also found to be re-
duced compared with baseline at every time point studied,
following idursulfase treatment. In addition, the liver and
spleen were no longer palpable in significant proportions
of patients at each time point. Although the estimation of
liver and spleen size by palpation is standard clinical prac-
tice in the management of patients with MPS II [18, 28,
38], other methods are available that facilitate the deter-
mination of organ size with greater accuracy. These in-
clude magnetic resonance imaging and abdominal
ultrasound [7–9, 25]. While the data collected in HOS can
be used to provide only general information on changes in
liver and spleen size, this still provides valuable informa-
tion on the effects of idursulfase treatment upon this com-
mon clinical manifestation of MPS II.
While our results show that there was a general trend for
improvement in all parameters assessed, we did observe
variation between patients in the changes from baseline in
each parameter assessed, similar to findings reported by
Tomanin et al. [25]. It has been suggested that ERT should
be initiated as soon as possible, to improve outcomes before
significant disease progression occurs [39]. Some of the
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variation seen in our study may reflect differences in the
age at start of treatment, since once onset of clinical disease
occurs it may be difficult to stabilize or prevent progression.
Additional contributing factors include the significant clin-
ical and genetic heterogeneity typically observed in MPS II
and the influence of genotype in determining the response
to treatment. The investigation of genetic factors was be-
yond the scope of our analysis. However, it will be import-
ant to investigate the influence of this beyond the partial
findings reported by Barbier et al. [40], as well as the impact
of other factors on the effectiveness of ERT in the future.
This study provides valuable real-world data on ERT
with idursulfase; however, there are several further limi-
tations to consider. Unlike a formal clinical trial, there
are no predetermined assessments in the registry and
only information collected during routine clinical prac-
tice is included. As a result, the methods and techniques
used for clinical assessments and laboratory assays are
not standardized and there may also be regional vari-
ation in the frequency of follow-up visits and the investi-
gations performed. It is also important to note that the
assessment of cognitive impairment recorded in HOS
varies between sites and is based on either the results of
standardized cognitive tests or on the clinical impression
of the treating physician. In addition, the voluntary, non-
interventional nature of HOS means that not all patients
included in this analysis had data available at baseline
and at each time point for each of the clinical parame-
ters investigated. For this reason, the number of patients
with data available was low for some parameters, and
patients whose data were included in the analyses for
each time point for any given parameter were not all
from the same cohort. Therefore, with the exception of
the analysis of the 83 patients who had data on uGAG
levels at all time points, it is not possible to directly
compare results from years 1, 2 and 3 of treatment and
draw any conclusions regarding sustained benefits.
It is also important to note that the number of patients
with data available was low for some parameters, particu-
larly at year 3. One reason for this is that assessments such
as pulmonary function tests and 6MWT distance are not
suitable for particular patient subgroups (e.g. those
<5 years of age and individuals with progressive cognitive
impairment) [9, 23, 41, 42]. However, almost half (48.5%)
of the patients included in this analysis started treatment
when they were less than 6 years old, and almost two
thirds (61.5%) were reported to have cognitive impairment
and so would not have had these types of tests. This high-
lights the need for other assessments of clinical effective-
ness that can be used for these individuals.
Despite these limitations, the results from this analysis
provide key insights into the impact of idursulfase treat-
ment on clinical manifestations of MPS II during the first
3 years of treatment, and complement and extend the
findings from the formal clinical trials and other smaller-
scale studies of idursulfase treatment. Given the progres-
sive nature and considerable variability in disease severity
of MPS II, stabilization of certain signs and symptoms of
the disease may indicate a positive effect of treatment, and
data collected in registries should continue to help to in-
crease our understanding of the benefits of ERT.
Conclusions
This analysis of HOS data suggests that idursulfase has a
positive effect on GAG storage (as evidenced by decreases
in uGAG levels and hepatosplenomegaly), as well as
6MWT, LVMI, FVC and FEV1 results after up to 3 years
of treatment. This indicates that findings from clinical tri-
als are also seen in routine clinical practice. Long-term
follow-up is particularly important for progressive disor-
ders such as MPS II and the data collected in registries are
playing an increasingly significant role in providing in-
sights into long-term treatment effects. In the future, as
the data become available, it will be important to investi-
gate the clinical outcomes of idursulfase treatment in pa-
tients enrolled in HOS over longer periods of follow-up.
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